Navidea Biopharmaceuticals Inc
Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic … Read more
Navidea Biopharmaceuticals Inc (NAVB) - Total Assets
Latest total assets as of September 2023: $5.70 Million USD
Based on the latest financial reports, Navidea Biopharmaceuticals Inc (NAVB) holds total assets worth $5.70 Million USD as of September 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Navidea Biopharmaceuticals Inc - Total Assets Trend (1992–2022)
This chart illustrates how Navidea Biopharmaceuticals Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Navidea Biopharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2022)
Navidea Biopharmaceuticals Inc's total assets of $5.70 Million consist of 73.3% current assets and 26.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 45.7% |
| Accounts Receivable | $630.00 | 0.0% |
| Inventory | $427.34K | 9.8% |
| Property, Plant & Equipment | $155.65K | 3.6% |
| Intangible Assets | $1.00 Million | 22.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1992–2022)
This chart illustrates how Navidea Biopharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Navidea Biopharmaceuticals Inc's current assets represent 73.3% of total assets in 2022, a decrease from 96.9% in 1992.
- Cash Position: Cash and equivalents constituted 45.7% of total assets in 2022, down from 66.2% in 1992.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 1.0% in 1992.
- Asset Diversification: The largest asset category is intangible assets at 22.9% of total assets.
Navidea Biopharmaceuticals Inc Competitors by Total Assets
Key competitors of Navidea Biopharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Navidea Biopharmaceuticals Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Navidea Biopharmaceuticals Inc generates 0.02x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Navidea Biopharmaceuticals Inc is currently not profitable relative to its asset base.
Navidea Biopharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.56 | 0.60 | 1.47 |
| Quick Ratio | 0.51 | 0.58 | 1.47 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-3.48 Million | $ -3.33 Million | $ 1.60 Million |
Navidea Biopharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Navidea Biopharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.16 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -34.2% |
| Total Assets | $4.37 Million |
| Market Capitalization | $10.01K USD |
Valuation Analysis
Below Book Valuation: The market values Navidea Biopharmaceuticals Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Navidea Biopharmaceuticals Inc's assets decreased by 34.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Navidea Biopharmaceuticals Inc (1992–2022)
The table below shows the annual total assets of Navidea Biopharmaceuticals Inc from 1992 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-12-31 | $4.37 Million | -34.21% |
| 2021-12-31 | $6.64 Million | -14.35% |
| 2020-12-31 | $7.76 Million | +86.90% |
| 2019-12-31 | $4.15 Million | -40.78% |
| 2018-12-31 | $7.01 Million | -66.27% |
| 2017-12-31 | $20.78 Million | +66.76% |
| 2016-12-31 | $12.46 Million | -16.73% |
| 2015-12-31 | $14.96 Million | +25.54% |
| 2014-12-31 | $11.92 Million | -70.43% |
| 2013-12-31 | $40.32 Million | +236.75% |
| 2012-12-31 | $11.97 Million | -61.62% |
| 2011-12-31 | $31.19 Million | +187.16% |
| 2010-12-31 | $10.86 Million | +20.46% |
| 2009-12-31 | $9.02 Million | -6.25% |
| 2008-12-31 | $9.62 Million | +36.20% |
| 2007-12-31 | $7.06 Million | -12.08% |
| 2006-12-31 | $8.03 Million | -30.57% |
| 2005-12-31 | $11.57 Million | -24.70% |
| 2004-12-31 | $15.37 Million | +108.07% |
| 2003-12-31 | $7.39 Million | +4.31% |
| 2002-12-31 | $7.08 Million | -37.51% |
| 2001-12-31 | $11.33 Million | +49.60% |
| 2000-12-31 | $7.57 Million | -26.64% |
| 1999-12-31 | $10.32 Million | -13.94% |
| 1998-12-31 | $11.99 Million | -71.15% |
| 1997-12-31 | $41.57 Million | -34.91% |
| 1996-12-31 | $63.87 Million | +165.03% |
| 1995-12-31 | $24.10 Million | 0.00% |
| 1994-12-31 | $24.10 Million | +91.27% |
| 1993-12-31 | $12.60 Million | -3.08% |
| 1992-12-31 | $13.00 Million | -- |